EU grants $8.3 million for Parkinson's jab; GSK R&D Chief: Vaccine costs pose business hurdles;

> The EU has granted a consortium of top research teams €6 million ($8.3 million) to develop therapeutic vaccines against Parkinson's disease and multiple system atrophy. Release

> The upfront costs of vaccines pose a challenge to business, GlaxoSmithKline ($GSK) R&D Chief Moncef Slaoui told Bloomberg. Video

> Hilleman Laboratories, Merck's ($MRK) joint venture with Wellcome Trust, will use new packaging features to help improve coverage of India's routine immunization program. More

> Novavax's ($NVAX) MERS candidate blocked infection in laboratory studies. Release

> Scientists have used cells from a dog's kidney to produce an experimental vaccine for the deadly H7N9. More

> PaxVax has appointed Jim Connolly to its board of directors. Release

> Measles cases are at their highest level in nearly 20 years, a CDC report says. Story

And Finally... Future flu vaccines could be grown inside tobacco plants. More

Suggested Articles

As a new coronavirus spreads, vaccine researchers have started work on candidates against the virus—and one could enter the clinic in a few months.

Merck's HPV vaccine Gardasil is delivering blockbuster sales as demand surges. But high demand has caused somewhat of a supply constraint.

GSK's Shingrix has generated blockbuster sales early in the launch, but there's a lot of remaining opportunity, an exec said at JPM.